Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma
Standard
Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. / Weisel, Katja C; Weidmann, Eckhart; Anagnostopoulos, Ioannis; Kanz, Lothar; Pezzutto, Antonio; Subklewe, Marion.
In: International journal of hematology, Vol. 88, No. 4, 11.2008, p. 434-440.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma
AU - Weisel, Katja C
AU - Weidmann, Eckhart
AU - Anagnostopoulos, Ioannis
AU - Kanz, Lothar
AU - Pezzutto, Antonio
AU - Subklewe, Marion
PY - 2008/11
Y1 - 2008/11
N2 - Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders occur at an increasing frequency in various hereditary and acquired states of immune dysfunction. In a few cases of T-cell lymphoma, especially in angioimmunoblastic T-cell lymphoma (AILT), EBV-associated B-cell lymphoproliferative disorders have been reported. Here, we present two cases of EBV-associated B-cell lymphoma after treatment of T-cell lymphoma (AILT and peripheral T-cell lymphoma, unspecified, PTCL-NOS) with a regimen containing alemtuzumab and fludarabine. Conventional and immunohistological tissue staining showed the typical features of highly proliferating diffuse large B-cell lymphoma in both cases. The monoclonal B-cell population displayed EBV latency type III. At the time of diagnosis the cellular immune status of both patients was severely compromised with an absolute CD4 T-cell count below <120 microl(-1). Our observation supports the notion that combination of cytotoxic drugs and immunosuppressive antibodies in patients with T-cell lymphoma may severely aggravate the already present immunodeficiency. We suggest to monitor the cellular immune status in combination with the EBV load in high risk patients for early detection-and possibly intervention-of EBV-associated lymphoma.
AB - Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders occur at an increasing frequency in various hereditary and acquired states of immune dysfunction. In a few cases of T-cell lymphoma, especially in angioimmunoblastic T-cell lymphoma (AILT), EBV-associated B-cell lymphoproliferative disorders have been reported. Here, we present two cases of EBV-associated B-cell lymphoma after treatment of T-cell lymphoma (AILT and peripheral T-cell lymphoma, unspecified, PTCL-NOS) with a regimen containing alemtuzumab and fludarabine. Conventional and immunohistological tissue staining showed the typical features of highly proliferating diffuse large B-cell lymphoma in both cases. The monoclonal B-cell population displayed EBV latency type III. At the time of diagnosis the cellular immune status of both patients was severely compromised with an absolute CD4 T-cell count below <120 microl(-1). Our observation supports the notion that combination of cytotoxic drugs and immunosuppressive antibodies in patients with T-cell lymphoma may severely aggravate the already present immunodeficiency. We suggest to monitor the cellular immune status in combination with the EBV load in high risk patients for early detection-and possibly intervention-of EBV-associated lymphoma.
KW - Alemtuzumab
KW - Antibodies, Monoclonal
KW - Antibodies, Monoclonal, Humanized
KW - Antibodies, Neoplasm
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Cytarabine
KW - Epstein-Barr Virus Infections
KW - Female
KW - Herpesvirus 4, Human
KW - Humans
KW - Lymphoma, Large B-Cell, Diffuse
KW - Lymphoma, T-Cell
KW - Male
KW - Middle Aged
KW - Neoplasms, Second Primary
KW - Virus Latency
KW - Case Reports
KW - Journal Article
U2 - 10.1007/s12185-008-0176-2
DO - 10.1007/s12185-008-0176-2
M3 - SCORING: Journal article
C2 - 18839273
VL - 88
SP - 434
EP - 440
JO - INT J HEMATOL
JF - INT J HEMATOL
SN - 0925-5710
IS - 4
ER -
